fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Commission Recommends Zoning Changes at Mahr Park, West Noel

MADISONVILLE, Ky. (8/30/15) – Hopkins County Joint Planning Commission had its regularly scheduled meeting on Thursday,… Read More

UPDATED: 'He Fought the Law ... but, the Law Won'

UPDATED W/MORE INFO: MADISONVILLE, Ky. (8/30/15) ― A city policeman received a small laceration on his forehead after… Read More

Most Read This Week

August 24, 2015 11266

Teen Reports Slasher Attempted to Attack Him on…

by Doreen Dennis, SurfKY News
August 24, 2015 6221

Alleged Burglar Calls 911 to Report Fire

by SurfKY News
August 24, 2015 5127

UPDATE: Four Dead, Two Survive Boating Accident

by SurfKY News
August 27, 2015 4674

All is Well after MNHHS Lockdown

by Doreen Dennis, SurfKY News
August 24, 2015 4416

MPD Coducting Sobriety Checkpoints

by SurfKY News

Most Read This Month

August 06, 2015 16660

Muhlenberg Woman Reportedly Suffers Violent…

by SurfKY News
August 24, 2015 11266

Teen Reports Slasher Attempted to Attack Him on…

by Doreen Dennis, SurfKY News

Stories Trending Now

August 30, 2015 3002

UPDATED: 'He Fought the Law ... but, the Law Won'

by Doreen Dennis, SurfKY News
August 29, 2015 1653

UK Part of First Study on Marijuana Compound…

by SurfKY News
August 30, 2015 1503

Happenings, Meetings Listed for Following Week

by Tammy Holloway, SurfKY News
August 29, 2015 1197

Kentucky State Park Camping Deal Offered in…

by SurfKY News
August 29, 2015 1142

All Occasions Formals to Host Celebration to…

by Rita Dukes Smith, SurfKY News Director
August 29, 2015 1045

UK Student Gaming System to Support Learning for…

by SurfKY News
August 29, 2015 1030

Police Searching for Suspect for Attempted ATM…

by SurfKY News
August 30, 2015 986

Commission Recommends Zoning Changes at Mahr…

by Tammy Holloway, SurfKY News
August 30, 2015 639

Smoke Fills Business, Upstairs Apartment on Center

by Doreen Dennis, SurfKY News
August 29, 2015 578

Keeping the Faith - 'The Wisdom to Wait'

by SurfKY News